贵州三力制药股份有限公司关于公司及控股子公司与专业投资机构共同投资设立创业投资基金进展暨完成基金备案的公告

Investment Fund Overview - Guizhou Sanli Pharmaceutical Co., Ltd. has established the Guizhou Qianli Biomedical Venture Capital Fund Partnership (Limited Partnership) in collaboration with its subsidiary Yunnan Wudi Pharmaceutical Co., Ltd., and several investment partners, with a total committed capital of RMB 500 million [1] - The limited partners (LPs) have committed a total of RMB 450 million, accounting for 99.00% of the fund, with Guizhou Sanli contributing RMB 160 million (32.00%) and Yunnan Wudi contributing RMB 40 million (8.00%) [1] Fund Establishment Progress - The fund completed its business registration on December 25, 2024, and received its business license from the Market Supervision Administration of Guiyang City [2] - On March 28, 2024, the company held board and supervisory meetings to approve the re-signing of the partnership agreement for the fund [3] - The fund manager, Zhuyin Capital, notified that the fund has completed the filing procedures with the Asset Management Association of China and obtained the Private Fund Filing Certificate on April 1, 2025 [4]